Weight ManagementAlso known as: Trulicity, LY2189265
Dulaglutide
Once-weekly GLP-1 receptor agonist (Trulicity) FDA-approved for type 2 diabetes. Uses an Fc-fusion design for extended half-life. Third most-prescribed GLP-1 agonist behind semaglutide and tirzepatide.
Half-Life
~5 days
Dose Range
0.75-4.5 mg/week
Frequency
1× weekly
Vial Sizes
1.5 mg, 3 mg, 4.5 mg
Mechanism of Action
GLP-1 analog covalently linked to modified IgG4 Fc fragment via a small peptide linker. Resists DPP-4 degradation while maintaining GLP-1R activation for insulin secretion, glucagon suppression, and appetite reduction.
Source: PMID: 25236860 (AWARD trials)
Dosing Protocol
| Typical Dose | 0.75-4.5 mg/week |
| Frequency | 1× weekly |
| Half-Life | ~5 days |
| Common Vial Sizes | 1.5 mg, 3 mg, 4.5 mg |
Reconstitution Example
Vial
1.5 mg
Water
0.5 mL
Concentration
3 mg/mL
Per Unit (100u syringe)
30 mcg
Dose of 750 mcg = 25 units on a 100-unit insulin syringe
Dosing Quick Reference
Dulaglutide— Dosing Guide
Dose Range
0.75-4.5 mg/week
Half-Life
~5 days
Frequency
1× weekly
Route
Subcutaneous
1.5 mg vial3 mg vial4.5 mg vial
💧 0.5 mL BAC water|📐 3 mg/mL concentration|💉 30 mcg/unit (100u syringe)
Weight Managementcalcmypeptide.com
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code